Introduction {#sec1_1}
============

Acute stroke treatment has evolved significantly over the last two decades, which is in part due to an improved understanding of factors that determine outcome \[[@B1]\]. It is now well understood that the site of arterial occlusion critically influences outcome following acute anterior circulation ischemic stroke \[[@B2],[@B3]\]. However, the majority of studies investigating this issue has focused on proximal large artery occlusion involving the internal carotid artery (ICA) and proximal middle cerebral artery (MCA) as these represent a particular challenge for medical management \[[@B2],[@B3],[@B4]\]. For example, recanalization following intervention in ICA and proximal MCA occlusion has been reported to be generally poor \[[@B2],[@B3],[@B4]\], and has been associated with larger infarct volumes and rarely with good functional outcomes (\<40%) even in affected patients with aggressive interventions \[[@B2],[@B3],[@B4],[@B5],[@B6]\]. Conversely, distal MCA occlusions have been associated with higher rates of recanalization following intervention, smaller infarct volumes, and a favorable outcome in the majority of patients (\>50%) \[[@B2],[@B3],[@B4]\]. Yet, the number of investigated patients in these studies was relatively small (n ≤ 100) and most (\>80%) were subjected to intravenous (i.v.) or endovascular recanalization approaches. Hence, there remains a paucity of information regarding factors modulating outcome following isolated distal MCA occlusion.

Therefore, we sought to investigate predictors of 90-day functional outcome in patients with infarction due to isolated M2 segment occlusion. Specifically, we assessed for factors associated with a good versus poor 90-day outcome (primary outcome) as well as 90-mortality (secondary outcome).

Methods {#sec1_2}
=======

Study Population {#sec2_1}
----------------

This study was a retrospective analysis of our prospective database including consecutive acute ischemic stroke patients admitted to a single academic center from January 2010 to August 2012. Only patients with isolated M2 occlusion on computed tomography angiography (CTA) performed at admission were included.

All patients underwent head CT or brain magnetic resonance imaging (MRI) within 7 days after ischemic stroke. Patient demographics, comorbidities, preadmission medications, laboratory data, intubation, requirement for admission at the intensive care unit (ICU), length of hospital stay (LOS), treatment modality \[conservative management vs. acute intervention (i.v. thrombolysis and endovascular recanalization)\], and stroke etiology \[according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification\] \[[@B7]\] after completion of diagnostic evaluation were collected in all patients. Admission National Institutes of Health Stroke Scale (aNIHSS) and modified Rankin Scale (mRS) scores were assessed at the time of presentation and at 90 days by a stroke-trained physician or study nurse certified in mRS \[[@B8]\]. This study was reviewed and approved by our Institutional Review Board.

Image Review and Analysis {#sec2_2}
-------------------------

CT, CTA, and diffusion-weighted imaging were reviewed independently by study physicians masked to clinical data, follow-up scans, patient variables, and outcomes. Details of the used imaging protocols have been previously described \[[@B9]\]. The MCA-M2 segment was defined as the segment extending from the bifurcation/trifurcation of the MCA to the top of the Sylvian fissure to further division \[[@B10]\]. The M2 portion was conceptually further divided into three segments of equal length: proximal, middle, and distal. The ischemic lesion volume was measured manually on follow-up imaging. Hemorrhagic transformation was defined according to the European Cooperative Acute Stroke Study II (ECASS II) criteria \[[@B11]\]. For analysis, hemorrhagic transformation was dichotomized into parenchymal hemorrhage (PH) versus non-PH.

Statistics {#sec2_3}
----------

Continuous variables are reported as mean ± SD or as median ± interquartile range (IQR). Categorical variables are reported as proportions. The primary analysis was performed to determine factors associated with a good 90-day outcome (mRS 0-2). In light of significant mortality, we further sought to investigate for factors that were independently associated with 90-day mortality in a secondary analysis. Receiver operating characteristic (ROC) curves were plotted to determine the optimal cut point for continuous variables (aNIHSS, age, and infarct volume) predicting a good 90-day outcome and mortality, respectively.

Between-group comparisons for continuous variables were made with unpaired t test, Mann-Whitney U test, and Kruskal Wallis with post hoc Dunn\'s method. Categorical variables were compared using the χ^2^ test or Fisher exact test as appropriate. Variables significantly associated with 90-day outcome in the univariable analysis (p \< 0.05) were included in the multivariable logistic regression model with backward elimination (likelihood ratio) to identify independent predictors for a good 90-day outcome or 90-day mortality, respectively.

Two-sided significance tests were used throughout and p \< 0.05 was considered statistically significant. All statistical analyses were performed using IBM® SPSS® Statistics 20.0.0 (IBM®, Armonk, N.Y., USA).

Results {#sec1_3}
=======

During the study period, 1,269 patients were admitted for acute ischemic stroke. Of these, 202 patients had an MCA occlusion confirmed by imaging and 106 of them had an occlusion distal to the bifurcation. Sixteen patients with an M3 occlusion were excluded. Thus, 90 patients with isolated M2 occlusions were included for analysis (fig. [1](#F1){ref-type="fig"}).

Primary Analysis {#sec2_4}
----------------

The majority of patients (69%) had a good 90-day outcome (fig. [2](#F2){ref-type="fig"}). Baseline characteristics of the included patients as stratified by good (mRS score ≤2) versus poor (mRS score \>2) outcome are summarized in table [1](#T1){ref-type="table"}. In univariable analysis (table [1](#T1){ref-type="table"}), factors associated with a poor 90-day outcome were older age (p = 0.014), a higher aNIHSS (p \< 0.001), admission at the intensive care unit (p = 0.002), intubation (p = 0.001), LOS (p = 0.003), presence of proximal M2 occlusion (p = 0.024), greater infarct volume (p \< 0.001), presence of both cortical and subcortical infarcts (p = 0.004), and PH-type conversion (p = 0.036). ROC curve analyses indicated that an aNIHSS ≤10 (sensitivity = 0.836, specificity = 0.931, AUC = 0.917, p \< 0.001), age ≤80 years (sensitivity = 0.721, specificity = 0.690, AUC = 0.673, p = 0.008), and infarct volume ≤26 ml (sensitivity = 0.902, specificity = 0.862, AUC = 0.925, p \< 0.001) best predicted a good 90-day outcome.

Multivariable logistic regression analysis indicated that age ≤80 years (OR 0.045, 95% CI 0.005-0.435, p = 0.007), aNIHSS ≤10 (OR 0.073, 95% CI 0.014-0.387, p = 0.002), and infarct volume ≤26 ml (OR 0.018, 95% CI 0.002-0.166, p \< 0.001) were significant predictors of good 90-day outcome (mRS score 0-2) (table [2](#T2){ref-type="table"}). When aNIHSS, age, and infarct volume were entered as continuous variables, multivariable analysis showed that a lower aNIHSS and smaller infarct volume (p = 0.001) were independently associated with a good 90-day outcome (online suppl. table [1](#S1){ref-type="supplementary-material"}; for all online suppl. material, see [www.karger.com/doi/10.1159/000360075](www.karger.com/doi/10.1159/000360075)).

Secondary Analysis {#sec2_5}
------------------

In contrast to the overall good outcome in our patient cohort, a significant proportion of patients with a poor outcome (64%) had died by 90 days. In secondary analyses, we sought to investigate for potential unique predictors of mortality. Baseline characteristics of patients as stratified by mortality are shown in online supplementary table [2](#S1){ref-type="supplementary-material"}. Older age (p = 0.011), congestive heart failure (CHF) (p = 0.007), higher aNIHSS (p \< 0.001), ICU admission (p = 0.009), intubation (p = 0.002), LOS (p = 0.026), proximal M2 occlusion (p = 0.017), greater infarct volume (p \< 0.001), and presence of both cortical and subcortical infarcts (p = 0.039) were predictors of 90-day mortality. ROC curve analyses indicated that an aNIHSS \>10 (sensitivity = 0.944, specificity = 0.722, AUC = 0.852, p \< 0.001), age \>80 years (sensitivity = 0.778, specificity = 0.681, AUC = 0.685, p = 0.015), and infarct volume of \>28 ml (sensitivity = 0.833, specificity = 0.806, AUC = 0.877, p \< 0.001) best predicted 90-day mortality (online suppl. table [2](#S1){ref-type="supplementary-material"}).

Multivariable analysis showed that an infarct volume \>28 ml (OR 11.874, 95% CI 2.630-53.604, p = 0.001) and age \>80 years (OR 4.953, 95% CI 1.087-22.563, p = 0.039) were independently associated with 90-day mortality (table [3](#T3){ref-type="table"}). In addition, need for intubation (OR 7.788, 95% CI 1.072-56.604) and history of CHF (OR 5.819, 95% CI 1.140-29.695) emerged as unique predictors of 90-day mortality (table [3](#T3){ref-type="table"}). When infarct volume, aNIHSS, and age were entered as continuous variables, need for intubation (p = 0.009) and CHF (p = 0.036) remained significantly associated with 90-day mortality (online suppl. table [3](#S1){ref-type="supplementary-material"}).

Discussion {#sec1_4}
==========

In this observational cohort study of stroke patients with M2 occlusions, we found that functional outcomes predominantly fall in two extremes. While most patients will have a good functional outcome by 90 days, the majority of patients with a poor outcome will have died by that time point. The former observation adds to the notion that patients with M2 occlusion have a generally favorable outcome. Prior studies on patients receiving intravenous thrombolysis and/or endovascular therapy showed high recanalization rates and good outcomes in 50-70% of cases \[[@B2],[@B3],[@B4],[@B12],[@B13],[@B14]\]. However, since the majority of studied patients received i.v. recombinant tissue plasminogen activator (rtPA), it is difficult to extrapolate these findings to patients that are ineligible to systemic (or endovascular) recanalization strategies. Interestingly, despite the fact that ∼75% of patients in our study were not subjected to acute recanalization therapy, the good outcome rates were at the upper limit of previously published ranges \[[@B2],[@B3],[@B4],[@B12],[@B13],[@B14]\]. This observation is important because it might explain why some studies did not note robust functional improvement with i.v. rtPA treatment in patients with distal MCA occlusion \[[@B15],[@B16],[@B17]\]. The reasons for overall good outcome in untreated patients are likely related to smaller clot burden leading to spontaneous recanalization as well as sparing of lenticulostriate arteries, which together results in smaller infarct volumes \[[@B5],[@B6],[@B12],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22]\]. Our data supports this hypothesis, as surrogate markers of a large lesion volume such as proximal M2 occlusion and cortical plus subcortical infarction were associated with worse outcome in unadjusted (but not adjusted) analyses. More importantly, consistent with other stroke studies, the absolute lesion volume was the most significant outcome predictor \[[@B4],[@B5],[@B6],[@B19]\]. In this respect, it is notable that the herein defined lesion volume cut point best predicting a favorable outcome was ≤26 ml, which is remarkably consistent with previously defined lesion size cutoffs associated with a good outcome \[[@B5],[@B6],[@B17]\].

In addition to lesion volume, our data confirms the importance of advanced age as well as higher aNIHSS as critical determinants of outcome \[[@B23],[@B24],[@B25]\]. Specifically, we found that age ≥80 years was associated with a worse prognosis consistent with generally worse outcome after ischemic stroke in octogenarians.

Recent endovascular therapy-based trials did not show a significant benefit over i.v. thrombolysis with rtPA \[[@B26]\]. In this respect our findings may provide valuable information for a future endovascular trial design as it may help identify and exclude patients that are 'too good' (or too poor) to be treated.

Notably, 64% of patients with a poor outcome had died by 90 days. This is in stark contrast to the observed good outcome in \>70% of investigated patients. Advanced age, greater infarct volume, history of CHF and need for intubations were independently associated with 90-day mortality. Thus, our study expands on previous observations by confirming these as important risk factors allowing for the identification of a subpopulation of patients with likely very poor outcome after isolated M2 occlusion, and thus aid guiding clinicians in patient management as well as counseling family members.

The strengths of our study relate to the analysis of a large and well-defined patient population with investigation of prospectively collected variables that have been associated with clinical outcome after ischemic stroke as well as masked assessment of data and standardized assessment of 90-day outcome in all patients. Our inclusion of a high number of untreated patients provides important information regarding the natural history of isolated M2 occlusions. Finally, we included volumetric analyses in our predictive models, which is important because infarct volume is increasingly recognized as a key predictor of outcome. The prospective collection of a large number of clinically relevant variables contributed to improved data quality while limiting the potential for misclassification.

Limitations of our study relate to its retrospective design. Further, CTA was obtained at the treating stroke physician\'s discretion, which may have biased the selection of patients having worse clinical presentation and outcomes. However, outcome rates were comparable to those published as part of prior studies rendering this possibility less likely \[[@B2],[@B3],[@B4],[@B12],[@B13],[@B14]\]. Given our study design and the limited number of patients that received thrombolytic therapy, the therapeutic efficacy of rtPAs could not be ascertained in this patient population. Lastly, future studies may benefit from assessing the acute lesion volume by defining the Alberta Stroke Program Early Computed Tomography Score (ASPECTS), which has the potential for risk stratification in the hyperacute setting \[[@B27],[@B28]\].

In conclusion, this study shows generally good outcome after isolated M2 occlusion and confirms the predictive importance of age, aNIHSS, and lesion volume. Additionally, we provide novel information regarding unique predictors for mortality in this group of patients with otherwise favorable outcome. Such information may aid in risk stratification to help with clinical management as well as to counsel patients and their families.
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###### 

Baseline characteristics (unadjusted) of the studied patient population as stratified by good 90-day outcome (mRS score 0--2)

  Characteristics                              All patients (n = 90)   Good outcome (mRS 0--2; n = 61)   Poor outcome (mRS 3--6; n = 29)   p value
  -------------------------------------------- ----------------------- --------------------------------- --------------------------------- ---------
  Age, years                                   73 ± 15                 70 ± 16                           78 ± 13                           0.014
  Female sex                                   50 (55.6)               31 (50.8)                         19 (65.5)                         n.s.
  Median aNIHSS (IQR)                          8 (4--16)               6.8 (4--8)                        18 (12--24)                       \<0.001
  Final TOAST stroke mechanisms                                                                                                            n.s.
   Large artery atherosclerosis                8 (9)                   7 (11.5)                          1 (3.4)                           
   Cardioembolic stroke                        49 (54)                 31 (51)                           18 (62)                           
   Stroke of other/undetermined cause          32 (36)                 22 (36)                           10 (34.5)                         
  Acute intervention                                                                                                                       n.s.
   Conservative management                     67 (74)                 45 (74)                           22 (76)                           
   i.v. rtPA                                   23 (26)                 16 (26)                           7 (24)                            
   Endovascular intervention\*                 5 (5.6)                 5 (8.2)                           0 (0)                             
  Imaging data                                                                                                                             
   Final infarct volume, ml                    28 ± 32                 12.5 ± 14.7                       60.4 ± 35                         \<0.001
   PH type conversion                          5 (5.6)                 1 (1.6)                           4 (14)                            0.036
   Proximal M2 occlusion                       37 (41)                 20 (33)                           17 (59)                           0.024
   Cortical plus subcortical infarction        11 (12)                 3 (5)                             8 (28)                            0.004
  Serum markers                                                                                                                            
   HbA1c                                       6.3 ± 1.1               6.4 ± 1.1                         6.3 ± 1.2                         n.s.
   Glucose at admission, mg/dl                 140 ± 55                140 ± 57                          141 ± 50                          n.s.
   Creatinine at admission, mg/dl              1.06 ± 0.51             1.1 ± 0.37                        1.14 ± 0.69                       n.s.
   White blood cells at admission, ×10^3^/μl   8.6 ± 2.7               8.4 ± 2.9                         9.3 ± 2.2                         n.s.
   LDL-C, mg/dl                                93 ± 38                 97 ± 39                           85 ± 36                           n.s.
   HDL-C, mg/dl                                46 ± 15                 45 ± 14                           48 ± 16                           n.s.
  Preadmission medications                                                                                                                 
   Antiplatelets                               40 (44)                 30 (49)                           10 (34)                           n.s.
   Oral anticoagulation                        9 (10)                  6 (10)                            3 (10)                            n.s.
   Statin                                      30 (33)                 20 (33)                           10 (34)                           n.s.
   Antiglycemic                                19 (21)                 15 (250)                          4 (14)                            n.s.
   Antihypertensive                            57 (63)                 38 (62)                           19 (66)                           n.s.
  Preexisting risk factors                                                                                                                 
   Hypertension                                71 (79)                 47 (77)                           24 (83)                           n.s.
   Dyslipidemia                                51 (56)                 37 (60)                           14 (48)                           n.s.
   Diabetes                                    31 (34)                 24 (39)                           7 (24)                            n.s.
   Prior stroke or transient ischemic attack   13 (14)                 8 (13)                            5 (17)                            n.s.
   Atrial fibrillation                         28 (31)                 17 (28)                           11 (38)                           n.s.
   Coronary artery disease                     27 (30)                 17 (28)                           10 (34)                           n.s.
   Congestive heart failure                    18 (20)                 9 (15)                            9 (31)                            n.s.
   Renal failure                               2 (2)                   1 (2)                             1 (3)                             n.s.
   Cancer                                      7 (8)                   5 (8)                             2 (7)                             n.s.
   Peripheral vascular disease                 6 (7)                   6 (10)                            0 (0)                             n.s.
   Current smoking                             22 (24)                 18 (29)                           4 (14)                            n.s.
   Alcohol abuse                               7 (8)                   5 (8.2)                           2 (7)                             n.s.
  Admission at ICU                             61 (68)                 35 (58)                           26 (90)                           0.002
  Intubation                                   12 (13)                 3 (5)                             9 (31)                            0.001
  Length of stay, days                         4 (2--6)                3 (2--5)                          6 (3--11)                         0.003

Data are n (%) or mean ± SD, except otherwise indicated. \* With or without i.v. rtPA.

###### 

Multivariable logistic regression analysis with backward elimination of factors independently associated with a good 90-day outcome (mRS score 0--2)

  Independent variable                           Coefficient (95% CI)   p value
  ---------------------------------------------- ---------------------- ---------
  Infarct volume ≥26 ml                          0.018 (0.002--0.166)   \<0.001
  aNIHSS ≥10[^\*^](#T2F1){ref-type="table-fn"}   0.073 (0.014--0.387)   0.002
  Age ≥80 years                                  0.045 (0.005--0.435)   0.007

When entered as continuous variables, the results did not meaningfully change.

###### 

Multivariable logistic regression analysis with backward elimination of factors independently associated with 90-day mortality

  Independent variable    Coefficient (95% CI)     p value
  ----------------------- ------------------------ ---------
  Infarct volume ≥28 ml   11.874 (2.630--53.604)   0.001
  CHF                     5.819 (1.140--29.695)    0.034
  Age ≥80 years           4.953 (1.087--22.563)    0.039
  Intubation required     7.788 (1.072--56.604)    0.043
